The 17th International Conference on Alzheimer's disease and Dementia will take place in Edinburgh, Scotland, on June 19–20, 2023. All speakers, delegates, and academics from across the world will be present at this conference. The goal of this conference is to raise public awareness.
Multiple Sclerosis:
Multiple sclerosis is a chronic demyelinating disease of the central nervous system that gradually strips away the myelin sheath from neuronal axons as a result of an immune response. Depending on where the lesion is, the resulting slowdown in signal transduction causes a loss of functioning that can involve both cognitive and movement disability.
The release of antigens such as myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein is thought to be the cause of the bouts of escalating inflammation that characterize the course of multiple sclerosis. Depending on the level of inflammation, multiple sclerosis manifests as a spectrum; the majority of individuals have early relapsing and remitting bouts of neuronal degeneration after a triggering event.
Alzheimer’s disease:
Alzheimer's disease (AD), sometimes known simply as Alzheimer's, is a chronic neurological condition that normally develops slowly and worsens with time. It is the cause of 60% to 70% of dementia cases. Short-term memory loss and difficulty recalling recent events are the most well-known early adverse effects. Indicators of the illness include behavior problems, linguistic problems, disorientation (including effectively getting lost), mood swings, loss of motivation, not managing self-care, and lack of inspiration. As a person's condition deteriorates, they typically distance themselves from their family and society. The biological function gradually declines, eventually resulting in death.
Past Affiliates:
Chaka Fattah:
Mr. Fattah has built on his expertise through on-site science-extensive briefings at the leading brain science laboratories at Harvard University, Stanford University, University of Pennsylvania, and Massachusetts Institute of Technology. All the Fortune 500 companies, such as Microsoft, Google, Facebook, and Twitter, and large organizations, such as the National Football League, have interacted with Mr. Fattah around their shared interests in neuroscience. Mr. Chaka Fattah has also attended briefings at the National Science Foundation, National Institutes of Health, and Veterans Administration and had on-site briefings at ten of the U.S. national labs.
Cigdem Akman:
Dr. Akman is a professor of neurology at the Columbia University Irving Medical Center and director of the Division of Child Neurology at the Vagelos College of Physicians and Surgeons' Departments of Neurology and Pediatrics.
Dr. Akman received her education in Ankara, Turkey, where she also earned a degree in medicine with honors from Ankara University. Following a residency in Clinical Neurophysiology and Epilepsy at Boston Children's Hospital, Harvard Medical School, Dr. Akman finished her studies in Child Neurology at the State University of New York. Dr. Akman then joined the Columbia University Irving Medical Center's Pediatric Epilepsy Program and Division of Child Neurology, where she participated in clinical education and patient treatment up until 2008.
Market Analysis:
The size of the worldwide market for Alzheimer's therapies was estimated at USD 4.04 billion in 2021, and it is anticipated to rise at a CAGR of 16.2% from 2022 to 2030. Market development is expected to be energized by the rising prevalence of Alzheimer's illness and the endorsement of infection-altering medicines. As per the NCBI, there were around 6.2 million Americans 65 and older who had Alzheimer's sickness in 2021; this number is predicted to rise to practically 13.8 million by 2060. Women are more prone to be diagnosed with Alzheimer's disease than men due to their longer life expectancy of women. Additionally, Alzheimer's disease is increasingly the leading cause of mortality among neurodegenerative illnesses and a common cause of physical disability that require immediate treatment.
Kindly register here- https://alzheimersdisease.neuroconferences.com/registration.php